Treatment with the drug candidate, acquired as part of the purchase of US biotech firm Chinook for up to $3.5 billion, resulted in a meaningful improvement in proteinuria in patients suffering from IgA nephropathy when compared to placebo, the Swiss drugmaker said in a statement., Treatment with the drug candidate, acquired as part of the purchase of US biotech firm Chinook for up to $3.5 billion, resulted in a meaningful improvement in proteinuria in patients suffering from IgA nephropathy when compared to placebo, the Swiss drugmaker said in a statement., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way